SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

1. PRODUCT AND COMPANY IDENTIFICATION
Product name:Finasteride (3.25%) Formulation

Manufacturer or supplier's details
Company: Organon & Co.
Address:JL Raya Pandaan KM. 48
Pandaan, Jawa Timur - Indonesia

Telephone:+1-551-430-6000

Emergency telephone number :+1-215-631-6999

E-mail address

EHSSTEWARD@organon.com:

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical
Restrictions on use: Not applicable

2. HAZARDS IDENTIFICATIONGHS Classification
Reproductive toxicity:

Category 1BSpecific target organ toxicity repeated exposure (Oral):

Category 2 (Testis)Long-term (chronic) aquatic
hazard:Category 2

GHS label elements
Hazard pictograms:

Signal word:

DangerHazard statements:

H360D May damage the unborn child.
H373 May cause damage to organs (Testis) through prolonged
or repeated exposure if swallowed.
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements:

Prevention:
P201 Obtain special instructions before use.
1 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

P202 Do not handle until all safety precautions have been readand understood.
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.
P391 Collect spillage.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste
disposal plant.
Other hazards which do not result in classification
None known.
3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance / Mixture:

MixtureComponents
Chemical name
Cellulose
StarchFinasteride

CAS-No.
9004-34-6
9005-25-8
98319-26-7

Concentration (% w/w)
< 10
< 10
>= 2.5 -< 10

4. FIRST AID MEASURES
General advice:

In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical
advice.

If inhaled:

In case of skin contact:

In case of eye contact:

If swallowed:

If inhaled, remove to fresh air.
Get medical attention.
In case of contact, immediately flush skin with soap and plentyof water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
2 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Most important symptoms
and effects, both acute anddelayedProtection of first-aiders:

Notes to physician::

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

May damage the unborn child.
May cause damage to organs through prolonged or repeatedexposure if swallowed.
First Aid responders should pay attention to self-protection,and use the recommended personal protective equipment
when the potential for exposure exists (see section 8).
Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES
Suitable extinguishing media:

Unsuitable extinguishingmedia
Specific hazards during firefighting
Hazardous combustion products:

Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical
None known.

:

Exposure to combustion products may be a hazard to health.

:

Carbon oxides
Metal oxides

Specific extinguishing methods:

Special protective equipment
for firefighters:

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to doso.
Evacuate area.
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protec- :tive equipment and emergency procedures

Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:

Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages
cannot be contained.

Methods and materials forcontainment and cleaning up:

Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items
employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding
certain local or national requirements.

7. HANDLING AND STORAGE
3 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Technical measures:

Local/Total ventilation:

Advice on safe handling:

Conditions for safe storage:

Materials to avoid:

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

See Engineering measures under EXPOSURE
CONTROLS/PERSONAL PROTECTION section.
If sufficient ventilation is unavailable, use with local exhaust
ventilation.
Do not get on skin or clothing.
Do not breathe dust, fume, gas, mist, vapours or spray.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety
practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to theenvironment.
Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Components with workplace control parameters
Components

CAS-No.

Value type
Control parameBasis(Form ofters / Permissible
exposure)
concentration
9004-34-6NAB
10 mg/m3
ID OELTWA
10 mg/m3
ACGIH
9005-25-8NAB
10 mg/m3
ID OEL
Further information: Not classified as carcinogenic to humans. Not
enough data to classify these materials as carcinogenic to humans or animals
TWA
10 mg/m3
ACGIH98319-26-7
TWA
0.5 µg/m3 (OEBInternal
5)
Wipe limit
5 µg/100 cm²Internal

Cellulose
StarchFinasterideEngineering measures:

Use closed processing systems or containment technologies
to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
All engineering controls should be implemented by facility
design and operated in accordance with GMP principles toprotect products, workers, and the environment.
No open handling permitted.
Totally enclosed processes and materials transport systems
are required.
Operations require the use of appropriate containment tech4 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

nology designed to prevent leakage of compounds into theworkplace.
Personal protective equipment
Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type
: Particulates type
Hand protection
Material:

Chemical-resistant gloves

Remarks
Eye protection::

Skin and body protection:

Hygiene measures:

Consider double gloving.
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions,mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is apotential for direct contact to the face with dusts, mists, oraerosols.
Work uniform or laboratory coat.
Additional body garments should be used based upon thetask being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentiallycontaminated clothing.
If exposure to chemical is likely during typical use, provide
eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review ofengineering controls, proper personal protective equipment,
appropriate degowning and decontamination procedures,industrial hygiene monitoring, medical surveillance and theuse of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance

:

solid

Colour

:

blue

Odour

:

odourlessOdour Threshold:

No data available

pH:

No data available

Melting point/freezing point:

No data available

Initial boiling point and boiling
range

:

No data available

5 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Flash point:

Not applicable

Evaporation rate:

Not applicable

Flammability (solid, gas):

Not classified as a flammability hazard

Flammability (liquids):

No data available

Upper explosion limit / Upper
flammability limit:

No data available

Lower explosion limit / Lower
flammability limit:

No data available

Vapour pressure:

Not applicable

Relative vapour density:

Not applicable

Relative density:

No data available

Density:

No data available

Solubility(ies)
Water solubility:

No data available

Partition coefficient: noctanol/water
Auto-ignition temperature:

Not applicable:

No data available

Decomposition temperature:

No data available

Viscosity
Viscosity, kinematic:

Not applicable

Explosive properties:

Not explosive

Oxidizing properties:

The substance or mixture is not classified as oxidizing.

Particle size:

No data available:::

Not classified as a reactivity hazard.
Stable under normal conditions.
Can react with strong oxidizing agents.

:::

None known.
Oxidizing agents
No hazardous decomposition products are known.

10. STABILITY AND REACTIVITY
Reactivity
Chemical stability
Possibility of hazardous reactions
Conditions to avoid
Incompatible materials
Hazardous decomposition

6 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

products
11. TOXICOLOGICAL INFORMATION
Information on likely routes of :exposure

Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.
Product:
Acute oral toxicity:

Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Cellulose:
Acute oral toxicity:

LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity:

LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity:

LD50 (Rabbit): > 2,000 mg/kg

Starch:Acute oral toxicity:

LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity:

LD50 (Rabbit): > 2,000 mg/kg

Finasteride:
Acute oral toxicity:

LD50 (Rat): 373 - 828 mg/kg

Components:

LD50 (Mouse): 486 mg/kg
Skin corrosion/irritation
Not classified based on available information.
Components:
Finasteride:
SpeciesResult::RabbitNo skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

7 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Components:
Starch:SpeciesResult::RabbitNo eye irritation

Finasteride:
Species
Remarks::

Rabbitslight irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.
Respiratory sensitisation
Not classified based on available information.
Components:
Starch:Test Type
Exposure routes
SpeciesResult::::Maximisation Test
Skin contact
Guinea pig
negative

Germ cell mutagenicity
Not classified based on available information.
Components:
Cellulose:
Genotoxicity in vitro:

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo:

Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Starch:Genotoxicity in vitro:

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Finasteride:
Genotoxicity in vitro:

Test Type: Chromosome aberration test in vitro
8 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Result: positive
Test Type: In vitro mammalian cell gene mutation test
Result: negative
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Alkaline elution assay
Result: negative
Genotoxicity in vivo:

Test Type: Mutagenicity (in vivo mammalian bone-marrowcytogenetic test, chromosomal analysis)
Application Route: Oral
Result: negative

Carcinogenicity
Not classified based on available information.
Components:
Cellulose:
Species
Application RouteExposure time
Result

:
:
:
:

Rat
Ingestion
72 weeks
negative

ResultTarget Organs
Remarks

:
:
:
:
:
:
:

Rat
Ingestion
2 Years
160 mg/kg body weight
negative
TestesBenign tumor(s)Species
Application RouteExposure time
ResultTarget Organs
Remarks

:
:
:
:
:
:

Mouse
Ingestion
19 month(s)negative
TestesBenign tumor(s):Test Type: One-generation reproduction toxicity study
Species: Rat

Finasteride:
Species
Application RouteExposure time

Reproductive toxicity
May damage the unborn child.
Components:
Cellulose:
Effects on fertility

9 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Application Route: Ingestion
Result: negative
Effects on foetal development

Finasteride:
Effects on fertility:

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative:

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Oral
Fertility: NOAEL: 80 mg/kg body weight
Result: No effects on fertility
Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Fertility: LOAEL: 80 mg/kg body weight
Result: positive
Remarks: There is no evidence that these findings are relevant to humans.

Effects on foetal development:

Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Developmental Toxicity: LOAEL: 0.003 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects.
Test Type: Embryo-foetal development
Species: Monkey
Application Route: Ingestion
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Teratogenic effects

Reproductive toxicity - Assessment:

Clear evidence of adverse effects on development, based onanimal experiments.

STOT - single exposure
Not classified based on available information.
STOT - repeated exposure
May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.
Components:
Finasteride:
Exposure routes
Target Organs
Assessment:::

Ingestion
Testis
Causes damage to organs through prolonged or repeatedexposure.
10 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Repeated dose toxicity
Components:
Cellulose:
Species
NOAEL
Application RouteExposure time

:
:
:
:

Rat
>= 9,000 mg/kg
Ingestion
90 Days

Starch:Species
NOAEL
Application RouteExposure time
Method

:
:
:
:
:

Rat
>= 2,000 mg/kg
Skin contact
28 Days
OECD Test Guideline 410

Finasteride:
Species
NOAEL
LOAEL
Application RouteExposure timeTarget Organs

:
:
:
:
:
:

Rat
20 mg/kg
40 mg/kg
Oral
1 yr
TestisSpecies
NOAEL
Application RouteExposure timeTarget Organs

:
:
:
:
:

Dog
45 mg/kg
Oral
1 yr
TestisAspiration toxicity
Not classified based on available information.
Experience with human exposure
Components:
Finasteride:
Ingestion:

Symptoms: breast tenderness, breast enlargement, impotence, lip swelling, skin rash:

LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h

12. ECOLOGICAL INFORMATION
Ecotoxicity
Components:
Cellulose:
Toxicity to fish

11 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Remarks: Based on data from similar materials
Finasteride:
Toxicity to fish:

LC50 (Oncorhynchus mykiss (rainbow trout)): 20.4 mg/l
Exposure time: 96 h
Method: FDA 4.11

Toxicity to daphnia and other :aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 17.8 mg/l
Exposure time: 48 h
Method: FDA 4.08

Toxicity to algae/aquaticplants:NOEC (Pseudokirchneriella subcapitata (green algae)): 49
mg/l
Exposure time: 14 h
Method: FDA 4.01

Toxicity to fish (Chronic toxicity):

NOEC (Oryzias latipes (Orange-red killifish)): 0.05 mg/l
Exposure time: 105 d

Toxicity to daphnia and other :aquatic invertebrates (Chronic toxicity)

NOEC (Daphnia magna (Water flea)): 0.12 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic
toxicity)

1:

Persistence and degradability
Components:
Cellulose:
Biodegradability:

Result: Readily biodegradable.

Finasteride:
Biodegradability:

Result: Not readily biodegradable.
Biodegradation: 0 %Exposure time: 7 dMethod: FDA 3.11

Stability in water:

Hydrolysis: 0 %(5 d)Method: FDA 3.09:

log Pow: 3.57

Bioaccumulative potential
Components:
Finasteride:
Partition coefficient: noctanol/water

12 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Mobility in soil
No data available
Other adverse effects
No data available
13. DISPOSAL CONSIDERATIONS
Disposal methods
Waste from residues:

Contaminated packaging:

Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATIONInternational Regulations
UNRTDGUN number
Proper shipping name

:
:

Class
Packing group
LabelsEnvironmentally hazardous

:
:
:
:

IATA-DGR
UN/ID No.
Proper shipping name::UN 3077
ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Finasteride)
9
III
9
yes

:
:
:
:

UN 3077
Environmentally hazardous substance, solid, n.o.s.
(Finasteride)
9
III
Miscellaneous
956

:

956

:

yes

IMDG-CodeUN number
Proper shipping name

:
:

Class
Packing group
LabelsEmS Code
Marine pollutant

:
:
:
:
:

UN 3077
ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Finasteride)
9III
9
F-A, S-F
yes

Class
Packing group
LabelsPacking instruction (cargo
aircraft)Packing instruction (passenger aircraft)
Environmentally hazardous

13 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC CodeNot applicable for product as supplied.
Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely
based upon the properties of the unpackaged material as it is described within this Safety Data
Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.
15. REGULATORY INFORMATION
Safety, health and environmental regulations/legislation specific for the substance or mixture
Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.
Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances
Hazardous to Health
Hazardous substances that must be registered: Not applicable
Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances
Hazardous substances approved for use: Not applicable
Prohibited substances:

Not applicable

Restricted substances:

Not applicable

Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous
Materials
Type of hazardous materials subject to distribution and : Not applicable
control, Annex I
Type of hazardous materials subject to distribution and :control, Annex II

Not applicable

The components of this product are reported in the following inventories:
AICS: not determinedDSL:

not determined

IECSC

:

not determined:

2023/09/30

16. OTHER INFORMATION
Revision Date

14 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

Further information
Sources of key data used tocompile the Safety Data
Sheet

:

Internal technical data, data from raw material SDSs, OECD
eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Date format:

yyyy/mm/dd

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
ID OEL: Indonesia. Occupational Exposure Limits
ACGIH / TWA
ID OEL / NAB::

8-hour, time-weighted averageLong term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport byLand of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute forStandardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with
x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;
ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with
x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA
- International Air Transport Association; IBC - International Code for the Construction andEquipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International
Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median
Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships;
n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) EffectConcentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable EffectLoading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New
Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No
1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance forsafe handling, use, processing, storage, transportation, disposal and release and shall not be
considered a warranty or quality specification of any type. The information provided relates only
to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.
Material users should review the information and recommendations in the specific context of their
15 / 16

SAFETY DATA SHEET

Finasteride (3.25%) Formulation
Version
2.1

Revision Date:
2023/09/30

SDS Number:
2160722-00015

Date of last issue: 2023/04/04
Date of first issue: 2017/11/09

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.
ID / EN

16 / 16